Document is current
Any future updates will be listed below
-
Authors
Suo, Chenqu
Polanski, Krzysztof https://orcid.org/0000-0002-2586-9576
Dann, Emma https://orcid.org/0000-0002-7400-7438
Lindeboom, Rik G. H. https://orcid.org/0000-0002-3660-504X
Vilarrasa-Blasi, Roser
Vento-Tormo, Roser https://orcid.org/0000-0002-9870-8474
Haniffa, Muzlifah
Meyer, Kerstin B. https://orcid.org/0000-0001-5906-1498
Dratva, Lisa M. https://orcid.org/0000-0002-2873-6787
Tuong, Zewen Kelvin https://orcid.org/0000-0002-6735-6808
Clatworthy, Menna R. https://orcid.org/0000-0002-3340-9828
Teichmann, Sarah A. https://orcid.org/0000-0002-6294-6366
- License Information
-
More Information
Article History
Received: 18 November 2022
Accepted: 7 March 2023
First Online: 13 April 2023
Competing interests
: In the past three years, S.A.T. has received remuneration for Scientific Advisory Board Membership from Sanofi, GlaxoSmithKline, Foresite Labs and Qiagen. S.A.T. is a cofounder and holds equity in Transition Bio. Z.K.T. has received consulting fees from Synteny Biotechnologies Ltd. on activities unrelated to this manuscript. The remaining authors declare no competing interests.
